COVID-19 Response Efforts - June 12, 2020

The State of Ohio Board of Pharmacy is committed to protecting the health and safety of Ohioans during the COVID-19 outbreak. This document outlines the Board's COVID-19 guidance and response efforts, including the issuance of waivers to assist our licensees in addressing operational needs, and will be updated regularly. **NOTE: At its June meeting, the Board made several updates to previously issued waivers. Updates can be found starting on Page 5 of this document: www.pharmacy.ohio.gov/COVID.**

For more information on the state's efforts to address coronavirus, visit www.coronavirus.ohio.gov or call 1-833-4-ASK-ODH.

Authorizing Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products
UPDATED 6/11/2020

IMPORTANT REMINDER: Per the FDA policy (see page 6), compounders **ARE NOT PERMITTED** to add other active or inactive ingredients, such as ingredients to improve the smell or taste due to the risk of accidental ingestion in children (examples include the use of essential oils). Different or additional ingredients may impact the quality and potency of the product.

Licensees that produce alcohol-based hand sanitizer products that contain inactive/active ingredients not authorized in the FDA policy must adjust their formulas accordingly and discontinue the sale of hand sanitizer that does not comply with the policy. Additionally, licensees are not permitted to sell any compounded hand-sanitizer that does not comply with the FDA policy. Failure to adhere to these requirements may subject a licensee and the licensee's responsible person to disciplinary action.

Mailing or Delivery of Non-Controlled Dangerous Drugs Personally Furnished by Prescribers
UPDATED 6/8/2020

Authorizes a licensed terminal distributor of dangerous drugs (TDDD) to mail or deliver non-controlled drugs to patients that have been personally furnished by a prescriber that is employed or contracted by the terminal distributor. This guidance can be accessed here.

Additional Delay of Drug Distributor Due Diligence Requirements
UPDATED 6/8/2020

The Board has delayed all drug distributor due diligence requirements until November 29, 2020.

More information on the delay of these requirements can be accessed here.